Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631876 · ClinicalTrials.gov registry record · Phase 3
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
A Phase 3 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
NCT02631876 is a Phase 3 study that has completed, run by ImmunoGen. The registered enrollment target is 366 participants.
The verdict
NCT02631876, a Phase 3 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
Study Summary
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Interventions
- DRUG Paclitaxel
- DRUG Topotecan
- DRUG Pegylated liposomal doxorubicin
- DRUG Mirvetuximab soravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2016-03-02 |
| Est. Completion | 2020-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631876
The ClinicalTrials.gov registry entry for NCT02631876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT02631876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631876 about?
NCT02631876 is a clinical study titled "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer". This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian t...
What is the current status of trial NCT02631876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2016-03-02. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02631876?
The interventions under investigation include: Paclitaxel (DRUG), Topotecan (DRUG), Pegylated liposomal doxorubicin (DRUG), Mirvetuximab soravtansine (DRUG).
Who is sponsoring clinical trial NCT02631876?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.